Skip to content
Search

Latest Stories

NHSGGC and Boehringer Ingelheim UKIE leading the charge in heart failure services

NHSGGC and Boehringer Ingelheim UKIE leading the charge in heart failure services
According to NHSGGC, the new heart failure care is set to create a blueprint for the rest of the nations

An ambitious partnership between NHS Greater Glasgow and Clyde (NHSGGC) and Boehringer Ingelheim UKIE is set to revolutionise heart failure care, potentially reshaping healthcare delivery across the UK.

The groundbreaking initiative aims to address the unmet needs of individuals living with heart failure with preserved ejection fraction (HFpEF) in North Glasgow, a population typically excluded from specialized services.


HFpEF is characterized by the heart's inefficient functioning and manifests through debilitating symptoms such as breathlessness, swelling with excess fluid (oedema) which often leads to hospitalisation and fatigue.

The project's cornerstone is a pioneering "home-first" approach, leveraging a multidisciplinary team to provide tailored care for over 4,000 HFpEF patients in Glasgow.

By focusing on early intervention and community-based support, the collaboration seeks to mitigate the economic burden of HFpEF on the NHS, reducing hospital admissions and enhancing patient outcomes.

Dr. Karen Hogg, Clinical Lead at NHSGGC, highlights the significance of this three-year long collaboration in identifying and addressing the unique challenges faced by HFpEF patients.

She said, "We know that this group of patients have frequent and long hospital admissions, impacting on quality of life, as well as a relatively poor prognosis.

Despite this, they do not have the same access to heart failure services that other patients with heart failures do."

With a focus on characterizing patient needs and optimizing treatment pathways, the project aims to set a new standard of care for those who are living with "preserved ejection fraction, multiple co-morbidities and complex medical needs within the Glasgow Royal Infirmary and Stobhill Hospital geographical area".

Moreover, the initiative has garnered praise from patient advocacy groups like the Pumping Marvellous Foundation, which emphasizes the importance of tailored care for HFpEF patients.

CEO Nick Hartshorne-Evans underscored the project's potential to drive equity in healthcare delivery, ensuring all individuals with heart failure receive guideline-driven treatments and specialist support.

Corroborating to this, Dr Christoph Zehendner, Medical Director at Boehringer Ingelheim UK and Ireland emphasised on the service being a "blueprint for NHS in Scotland, the UK and other countries" and said,

“We have a long history of supporting medical research with the NHS in Glasgow and are excited to now be working together on addressing this high unmet need in heart failure for people living with HFpEF."

More For You

Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less
Pharmacies in Northern Ireland distribute free booklets to raise cancer awareness

Dr Anna Cullen, Public Health Registrar at the Public Health Agency and Clare Conroy, Community Pharmacist from Meigh Pharmacy in Co Down.

Photo credit: Community Pharmacy Northern Ireland

Pharmacies in Northern Ireland help raise cancer awareness

Community pharmacies across Northern Ireland are distributing a free information booklet to help raise public awareness of the signs and symptoms of cancer and promote early diagnosis.

The initiative is part of the ‘Be Cancer Aware’ campaign, which has been running in pharmacies since April and will continue through May as part of the Living Well service.

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less